Skip to content

CAN-BIND-17 Optimized Predictive Treatment In Medications for Unipolar Major Depression (OPTIMUM-D)

Major Depressive Disorder | Depression | Emotion | Feeling guilty | worthless | or helpless | Signs of...

Major depressive disorder (MDD) is a common, life-disrupting and highly recurrent illness. Unfortunately, 30–40% of patients do not respond to currently available interventions. The research study we are conducting hopes to shorten the path from diagnosing a person with MDD to starting them on a right, or 'personalized', treatment plan. To achieve this we examine brain scans, clinical assessments and blood samples to gain a better understanding of depression and how best to treat it. we are.
To do so, we are seeking to recruit participants who either have major depressive disorder (MDD) and are currently experiencing symptoms of depression.
We are also recruiting healthy comparison participants.

null

Participation Requirements

  • Sex:

    Male, Female

  • Eligible Ages:

    18 to 65

Participation Criteria

Inclusion Criteria:
Inclusion criteria:
Patients with MDD must
1. Meet have a confirmed diagnosis of major depressive disorder
2. Agree to stop any medication before starting the study and being prescribed the study medication
3. Be fluent in English to understand the interviews and questionnaires.

Healthy Comparison Participants must
1. Not have a history of any psychiatric disorder
2. Not have any significant physical or medical condition (e.g., arthritis, fibromyalgia)
3. Be fluent in English to understand the interviews and questionnaires.
Exclusion Criteria:
Exclusionary criteria include:
1. Bipolar Disorder
2. Substance dependence/abuse in the past 6 months
3. Pregnancy or breastfeeding
4. Neurological disorders or head trauma
5. Having previously failed escitalopram or have shown an intolerance to escitalopram.

Study Location

University of Calgary
University of Calgary
Calgary, Alberta
Canada

Contact Study Team

Study Sponsored By
University of Calgary
Participants Required
More Information
Study ID: REB21-1606